Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Amgen Inc (AMGN) Ordinary US $ 0.01

Sell:$213.11 Buy:$213.18 Change: $0.50 (0.23%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Sell:$213.11
Buy:$213.18
Change: $0.50 (0.23%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Sell:$213.11
Buy:$213.18
Change: $0.50 (0.23%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Contact details

Address:
1 Amgen Center Dr
THOUSAND OAKS
91320-1730
United States
Telephone:
+1 (805) 4471000
Website:
www.amgen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AMGN
ISIN:
US0311621009
Market cap:
$121.30 billion
Shares in issue:
567.85 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
Dow Jones Industrial Average

Key personnel

  • Robert Bradway
    Chairman of the Board, President, Chief Executive Officer
  • Peter Griffith
    Chief Financial Officer, Executive Vice President
  • Jonathan Graham
    Executive Vice President, General Counsel, Secretary
  • Lori Johnston
    Executive Vice President - Human Resources
  • Murdo Gordon
    Executive Vice President - Global Commercial Operations
  • David Reese
    Executive Vice President - Research and Development
  • Esteban Santos
    Executive Vice President - Operations
  • David Piacquad
    Senior Vice President - Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.